Steroids Versus ECP and Steroids as First-line Treatment of Grade II Acute GVHD.

This document provides information about a clinical trial that is not yet recruiting participants. The trial aims to evaluate the effectiveness of a treatment for acute graft-versus-host disease (GVHD) in patients who have undergone allogeneic hematopoietic stem cell transplantation. The treatment involves a combination of extracorporeal photopheresis (ECP) and steroids. The trial will enroll 42 participants and is expected to be completed in January 2026. The eligibility criteria for participants are outlined, and the responsible party for the trial is the Central Hospital in Nancy, France. [Extracted from the article]